Antibody Discovery Service via Polyclonal Antibody Sequencing.
Mass spectrometry based in vivo antibody discovery. An end-to-end solution delivering developable, functional mAbs unseen by other technologies.
- A unique and exclusive set of candidate mAbs
- Work in any species
- Epitope diversity
- Functional from the start
Antibody Generation Platform
How It Works.
The novel technology behind our Antibody Generation platform gives us the ability to sequence antibody proteins directly from a complex mixture, using mass spectrometry. We call this technology REpAb®. This means one can access the actual functional native antibodies circulating in the blood, and take full advantage of the natural immune response.
Antibody Discovery Project Timeline
- Full mAB sequences with pair HC and LC
- Additional chains found in the sample
- CDR clusters
- Raw NGS data
- Affinity binding data from SPR
- Epitope mapping data from HDX-MS workflow
“Our cutting edge antibody discovery service can select the very best antibodies out of millions of naturally evolved forms. REpAb® starts with a complex mixture of antibodies known to have affinity for your target. From there, we employ proprietary chemistry and various separation techniques, followed by dozens of LC-MS/MS runs and other mass spectrometry experiments. The resulting data is analyzed by our own de novo sequencing and assembly algorithms to produce full length IgG sequences.
Quality vs Quantity of Hits.
We find the very best antibodies (typically 5-20) out of millions of naturally evolved forms, and can return additional sequence info for hundreds of antibodies in each cluster.
A variety of binding strength, typically in the picomolar to nanomolar affinity range. Kinetic profiling available to aid in selection (on rate, off rate, epitope binning).
Since we are isolating the functional native immune response from serum, our approach naturally selects for a variety of epitopes. Furthermore, it is biased towards the biologically relevant epitopes insofar as it is natural for the immune system to evolve to produce an abundance of antibodies that ‘work’.
Functional Screening and Validation.
Prior to REpAb® sequencing, the pAb itself can be put through a batter of functional assays to ensure the sample in the tube is fit-for-purpose. This overcomes limitations seen in single-cell isolation techniques which are known to suffer from very high attrition rates.
Immunogenicity and Developability.
REpAb® is an in vivo approach that isolates the native immune response. As such it reduces the risk of immunogenicity issues and provides highly developable leads.
Protein Sequencing Technology
REpAb® starts with a complex mixture of antibodies known to have affinity for your target (i.e. an affinity purified pAb). From there, we employ proprietary chemistry and various separation techniques, followed by dozens of LC-MS/MS runs and other mass spectrometry experiments. The resulting data is analyzed by our own de novo sequencing and assembly algorithms to produce full length IgG sequences.
Watch our webinar to see how it works >
Model Species and Cross Species Homology
REpAb® is species agnostic and can be used in almost any species and has been used with a variety of hosts to date: Rabbit, Alpaca, Sheep, Dog, Chicken, Human, Mouse, Goat, etc. We can test antibodies to ensure they work in other model species as part of your campaign.
We have experience with tolerance breaking strategies such as using novel immunization, adjuvant and modification techniques to elicit an immune response. Additionally, a unique advantage of the REpAb® platform for tolerance busting is using different host species to raise antibodies against conserved proteins.
“Rapid Novor was tasked with finding highly specific, high affinity antibodies against an important target- and they delivered powerful antibodies fit-for-purpose. Such antibodies are not easily obtained yet the Rapid Novor approach proved immediately successful, despite our time-constrained and stringent demands.”
Talk to Our Scientists.
We Have Sequenced 7000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 6000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics
Talk to our scientists. We have sequenced over 6000 antibodies and we are eager to help you.
Antibody Sequencing, Discovery and Proteomics Services.
Antibody Sequencing & Discovery Services.
Monoclonal antibody sequencing from small antibodysamples, no need for hybridoma or DNA information. Full sequence in record time.
Polyclonal antibody sequencing and antibody discovery service. Sequence antibodies from blood or a polyclonal mixture.
Antibody verification by real-time peptide mapping. Antibody sequence confirmation service for reproducibility.
Mass spec based epitope mapping. Epitope mapping for identify the binding site of an antibody to its corresponding antigen with the highest confidence and resolution.
Explore Epitope Mapping
Label-free evaluation of antibody-antigen binding relies on a Surface Plasmon Resonance technology. Combined with our expertise in antibody interactions, this results in high sensitivity and the lowest noise even in complex analytes.
Explore SPR Analysis
Quantify the immune response by accurately profiling the vast antibody-protein repertoire and its different isotypes, and subtypes in serum over time.
Explore Immune Response Profiling